Skip to main content

A National Cancer Clinical Trials System for the 21st Century Reinvigorating the NCI Cooperative Group Program (2010) / Chapter Skim
Currently Skimming:

Executive Summary
Pages 1-4

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 1...
... For example, companies may have less incentive to • conduct clinical trials to compare the effectiveness of different treatment options that are already approved for clinical use, • combine novel therapies developed by different sponsors, • develop therapies for rare diseases, • determine optimal duration and dose of treatment with drugs in clinical use, • test multimodality therapies, such as radiation therapy, surgery, or devices in combination with drugs, • study screening and prevention strategies, or • focus on rehabilitation and quality of life following therapy. The National Cancer Institute (NCI)
Read the entire page →
From page 2...
... The committee concluded that a robust, standing cancer clinical trials network is essential to effectively translate discoveries into clinical benefits for patients. There are hundreds of cancer therapies in development and a continuous need for design and implementation of new clinical trials, so it would be highly inefficient to fund and develop infrastructures and research teams separately for each new trial.
Read the entire page →
From page 3...
... focused on four broad goals to enhance the value of national Cooperative Group clinical trials in cancer: Consolidation and Efficiency. Improve the efficiency and reduce the average time for the design and launch of innovative clinical trials by consolidating functions, committees, and Cooperative Groups; streamlining oversight processes; facilitating collaboration; and streamlining and standardizing data collection and analysis.
Read the entire page →
From page 4...
... Incorporate innovative science and trial design into cancer clinical trials   5. Support and use biorepositories   6. Develop and evaluate novel trial designs   7. Develop standards for new technologies Goal III. Improve the means of prioritization, selection, support, and comple tion of cancer clinical trials   8. Reevaluate the role of NCI in the clinical trials system   9. Increase the accrual volume, diversity, and speed of clinical trials 10. Increase funding for the Cooperative Group Program Goal IV.
Read the entire page →

Key Terms

  • cancer clinical
  • patient care
  • innovative clinical
  • clinical trial
  • trials network

  • trial design
  • adequate funds
  • efficient clinical
  • conduct clinical
  • clinical investigators

  • clinical benefits
  • funded clinical
  • entire clinical
  • multidisciplinary clinical
  • cancer patients

  • trials play
  • incorporate innovative
  • cancer therapies
  • patient populations
  • diverse patient

  • improve patient
  • standing cancer
  • trials conducted
  • cancer patient
  • trials cooperative

  • trial completion
  • national cooperative
  • effectively translate
  • standard patient
  • addressing questions


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.